| Dr J Dustin Rosenhamer, MD | |
|
2216 Nw 164th St, Ste A, Edmond, OK 73013-9078 | |
| (405) 755-1515 | |
| Not Available |
| Full Name | Dr J Dustin Rosenhamer |
|---|---|
| Gender | Male |
| Speciality | Neurology |
| Experience | 17 Years |
| Location | 2216 Nw 164th St, Edmond, Oklahoma |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1558658138 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084N0400X | Psychiatry & Neurology - Neurology | 28605 (Oklahoma) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Scissortail Healthcare Llc | Tulsa, OK | Home health agency |
| Green Country Home Health Care Inc | Claremore, OK | Home health agency |
| Hillcrest Medical Center | Tulsa, OK | Hospital |
| Hillcrest Hospital South | Tulsa, OK | Hospital |
| Hillcrest Hospital Pryor | Pryor, OK | Hospital |
| Hillcrest Hospital Claremore | Claremore, OK | Hospital |
| Bailey Medical Center, Llc | Owasso, OK | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Ahs Oklahoma Physician Group Llc | 9436122496 | 298 |
News Archive
The U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) seeking marketing approval for Retigabine. In addition, the European Medicines Agency (EMEA) confirmed on November 17, 2009 that the MAA (Marketing Authorization Application) was successfully validated thus enabling the MAA review to commence.
Zalicus Inc. a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases today announced the successful completion of a Phase 1 clinical trial evaluating the pharmacokinetics and safety of a new formulation of Z160, a novel oral N-type calcium channel blocker.
A naturally occurring protein called TLR1 plays a critical role in protecting the body from illnesses caused by eating undercooked pork or drinking contaminated water, according to new research from the University of Southern California (USC).
A Cancer Genomics Browser developed by researchers at the University of California, Santa Cruz, provides a new way to visualize and analyze data from studies aimed at improving cancer treatment by unraveling the complex genetic roots of the disease.
Scientists at Johns Hopkins report they have figured out a key step in how "free" calcium - the kind not contained in bones - is managed in the body, a finding that could aid in the development of new treatments for a variety of neurological disorders that include Parkinson's disease.
› Verified 1 days ago
| Entity Name | Ahs Oklahoma Physician Group Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1235182775 PECOS PAC ID: 9436122496 Enrollment ID: O20040817001197 |
News Archive
The U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) seeking marketing approval for Retigabine. In addition, the European Medicines Agency (EMEA) confirmed on November 17, 2009 that the MAA (Marketing Authorization Application) was successfully validated thus enabling the MAA review to commence.
Zalicus Inc. a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases today announced the successful completion of a Phase 1 clinical trial evaluating the pharmacokinetics and safety of a new formulation of Z160, a novel oral N-type calcium channel blocker.
A naturally occurring protein called TLR1 plays a critical role in protecting the body from illnesses caused by eating undercooked pork or drinking contaminated water, according to new research from the University of Southern California (USC).
A Cancer Genomics Browser developed by researchers at the University of California, Santa Cruz, provides a new way to visualize and analyze data from studies aimed at improving cancer treatment by unraveling the complex genetic roots of the disease.
Scientists at Johns Hopkins report they have figured out a key step in how "free" calcium - the kind not contained in bones - is managed in the body, a finding that could aid in the development of new treatments for a variety of neurological disorders that include Parkinson's disease.
› Verified 1 days ago
| Entity Name | Mind And Body Medical Clinic |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1497223846 PECOS PAC ID: 9133464969 Enrollment ID: O20181221001735 |
News Archive
The U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) seeking marketing approval for Retigabine. In addition, the European Medicines Agency (EMEA) confirmed on November 17, 2009 that the MAA (Marketing Authorization Application) was successfully validated thus enabling the MAA review to commence.
Zalicus Inc. a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases today announced the successful completion of a Phase 1 clinical trial evaluating the pharmacokinetics and safety of a new formulation of Z160, a novel oral N-type calcium channel blocker.
A naturally occurring protein called TLR1 plays a critical role in protecting the body from illnesses caused by eating undercooked pork or drinking contaminated water, according to new research from the University of Southern California (USC).
A Cancer Genomics Browser developed by researchers at the University of California, Santa Cruz, provides a new way to visualize and analyze data from studies aimed at improving cancer treatment by unraveling the complex genetic roots of the disease.
Scientists at Johns Hopkins report they have figured out a key step in how "free" calcium - the kind not contained in bones - is managed in the body, a finding that could aid in the development of new treatments for a variety of neurological disorders that include Parkinson's disease.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr J Dustin Rosenhamer, MD 2108 Nw 173rd St, Edmond, OK 73012-7148 Ph: (405) 410-2477 | Dr J Dustin Rosenhamer, MD 2216 Nw 164th St, Ste A, Edmond, OK 73013-9078 Ph: (405) 755-1515 |
News Archive
The U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) seeking marketing approval for Retigabine. In addition, the European Medicines Agency (EMEA) confirmed on November 17, 2009 that the MAA (Marketing Authorization Application) was successfully validated thus enabling the MAA review to commence.
Zalicus Inc. a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases today announced the successful completion of a Phase 1 clinical trial evaluating the pharmacokinetics and safety of a new formulation of Z160, a novel oral N-type calcium channel blocker.
A naturally occurring protein called TLR1 plays a critical role in protecting the body from illnesses caused by eating undercooked pork or drinking contaminated water, according to new research from the University of Southern California (USC).
A Cancer Genomics Browser developed by researchers at the University of California, Santa Cruz, provides a new way to visualize and analyze data from studies aimed at improving cancer treatment by unraveling the complex genetic roots of the disease.
Scientists at Johns Hopkins report they have figured out a key step in how "free" calcium - the kind not contained in bones - is managed in the body, a finding that could aid in the development of new treatments for a variety of neurological disorders that include Parkinson's disease.
› Verified 1 days ago
Jonathan A Doyle, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 3444 S Boulevard, Edmond, OK 73013 Phone: 405-285-2260 Fax: 405-285-2280 | |
Dr. Kent Ragan Smalley, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 3432 Nw 178th St Ste A, Edmond, OK 73012 Phone: 405-696-3773 Fax: 405-757-6953 | |
Dr. Alicia D Thompson, M.D. Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 2908 Astoria Way, Edmond, OK 73034 Phone: 253-343-0116 Fax: 480-383-6454 | |
Daniel Pappas, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 15225 Fairview Farm Rd., Edmond, OK 73013 Phone: 405-627-5837 | |
Ms. Sarah Vaden Danielson, PA Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 2000 Sonoma Park Dr, Edmond, OK 73013 Phone: 405-285-2260 Fax: 405-285-2280 | |
Dr. Fatema Parveen Haque, M.D. Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 16909 Sunny Hollow Rd, Edmond, OK 73003 Phone: 405-844-2883 | |
Dr. Fei-ling Yeh Ii, D.O. Psychiatry & Neurology Medicare: May Accept Medicare Assignments Practice Location: 1616 S State St, Edmond, OK 73013 Phone: 405-844-7888 Fax: 405-844-8881 |